Is it too early to recommend local treatment in oligometastatic NSCLC: a plea for equipoise
Br J Radiol. 2024 Mar 27:tqae068. doi: 10.1093/bjr/tqae068. Online ahead of print.ABSTRACTOligometastatic Non-Small Cell Lung cancer (OMD NSCLC) has been proposed to bridge the spectrum between non-metastatic to widely metastatic states and is perceived as an opportunity for potential cure if removed. Twelve clinical trials on local treatment have been reported, yet none are conclusive. These trials informed the development of a joint clinical practice guideline (CPG) by the American & European societies for radiation oncology, which endorses local treatment for OMD NSCLC. However, the heterogeneity between and prognostic factors within these trials likely influenced outcomes and can only support guidance at this time. Caution against an uncritical acceptance of the guideline is discussed, as strong recommendations are offered based on expert opinion and inconclusive evidence. The guideline is also examined by a patient's caregiver, who emphasizes that uncertain evidence impedes shared decision-making.PMID:38538948 | DOI:10.1093/bjr/tqae068
Source: The British Journal of Radiology - Category: Radiology Authors: Irfan Ahmad Kundan Singh Chufal Alexis Andrew Miller Ram Bajpai Preetha Umesh Aashita Dawer Sarthak Tandon Senthilkumar Gandhidasan Bharat Dua Kratika Bhatia Munish Gairola Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Non-Small Cell Lung Cancer | Radiology | UK Health